home / stock / vvos / vvos news

VVOS News and Press, Vivos Therapeutics Inc. From 04/28/22

Stock Information
Company Name: Vivos Therapeutics Inc.
Stock Symbol: VVOS
Market: NASDAQ
Website: vivoslife.com
Menu
VVOS VVOS Quote VVOS Short VVOS News VVOS Articles VVOS Message Board
Get VVOS Alerts

News, Short Squeeze, Breakout and More Instantly...
VVOS - Vivos Therapeutics Schedules First Quarter 2022 Financial Results Conference Call

HIGHLANDS RANCH, Colo., April 28, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities ...
VVOS - InvestorNewsBreaks - Vivos Therapeutics Inc. (NASDAQ: VVOS) Opens Third US Multidisciplinary Sleep Apnea Clinic

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snorin...

VVOS - Vivos Therapeutics Opens Third U.S. Multidisciplinary Center to Treat Patients Suffering from Sleep Apnea with The Vivos Method

HIGHLANDS RANCH, Colo., April 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (NASDAQ: VVOS) (“Vivos'' or the “Company''), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients with...

VVOS - InvestorNewsBreaks - Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, Full-Year 2021 Financial, Operational Report

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea ("OSA") and snoring in adults, is ...
VVOS - Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q4 2021 Results - Earnings Call Transcript

Start Time: 17:00 End Time: 17:48 Vivos Therapeutics, Inc. (VVOS) Q4 2021 Earnings Conference Call March 31, 2022, 17:00 PM ET Company Participants Kirk Huntsman - Chairman and CEO Brad Amman - CFO Julie Gannon - IRO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Pres...

VVOS - Vivos Therapeutics GAAP EPS of -$0.96, revenue of $16.89M

Vivos Therapeutics press release (NASDAQ:VVOS): FY GAAP EPS of -$0.96. Revenue of $16.89M (+29.2% Y/Y). Shares -5%. Cash and cash equivalents were $24.0 million at December 31, 2021. For further details see: Vivos Therapeutics GAAP EPS of -$0.96, revenue of $16.89M

VVOS - Vivos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

Fourth Quarter Revenue Increased 33% Year-Over-Year While Full Year Revenue Increased 29% Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or the...
VVOS - InvestorNewsBreaks - Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Call to Review Q4, FY 2021 Financial Results

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring,...

VVOS - Vivos Therapeutics Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call

HIGHLANDS RANCH, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities ...

VVOS - InvestorNewsBreaks - Vivos Therapeutics Inc. (NASDAQ: VVOS) Selected Among 'World's Most Innovative Companies' by Fast Company Magazine

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snorin...
Previous 10 Next 10